技术文章

Recombinant Human GCDH Protein: Research Guide & Protocol

Recombinant Human GCDH Protein is a mitochondrial flavoenzyme that catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA, serving as a critical tool for biochemical, metabolic, and disease-mechanism research related to glutaric acidemia type 1.

Protein Name
Recombinant Human GCDH (Glutaryl-CoA Dehydrogenase) Protein
SKU
rp374277
Biological Function
Catalyzes oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA in lysine, hydroxylysine, and tryptophan catabolism
Subcellular Localization
Mitochondrial matrix
Cofactor
FAD (Flavin Adenine Dinucleotide)
Disease Relevance
Loss-of-function mutations in GCDH cause Glutaric Acidemia Type 1 (GA1), an autosomal recessive organic acidemia
Recommended Storage
-20°C or -80°C; avoid repeated freeze-thaw cycles (verify with CoA)

Protein Identity and Biological Background

Glutaryl-CoA Dehydrogenase (GCDH; UniProt Q92947) is a nuclear-encoded mitochondrial matrix enzyme belonging to the acyl-CoA dehydrogenase (ACAD) family. It functions as a homotetrameric flavoprotein, with each subunit non-covalently binding one molecule of FAD as its essential cofactor.

GCDH occupies a central position in the catabolic pathways of the amino acids L-lysine, L-hydroxylysine, and L-tryptophan. Its primary catalytic activity is the oxidative decarboxylation of glutaryl-CoA to yield crotonyl-CoA and CO2, coupled to the reduction of FAD to FADH2, which subsequently feeds electrons into the mitochondrial electron transport chain via the electron transfer flavoprotein (ETF).

Mutations in the GCDH gene lead to accumulation of glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine, underpinning the pathology of Glutaric Acidemia Type 1 (GA1; OMIM #231670), a rare autosomal recessive neurometabolic disorder that primarily affects the developing striatum.

Product Specifications and Quality Attributes

Recombinant Human GCDH Protein (SKU: rp374277) is manufactured using recombinant expression technology to deliver consistent, research-grade material. Key quality attributes typically assessed for this class of protein include:

  • Purity: Assessed by SDS-PAGE and/or HPLC; high-purity preparations are expected for enzymatic and binding studies. Confirm the exact purity specification on the Certificate of Analysis (CoA) supplied with each lot.
  • Biological Activity: Functional GCDH activity can be confirmed by a coupled spectrophotometric assay monitoring DCPIP or ETF reduction in the presence of glutaryl-CoA substrate.
  • Endotoxin Level: Endotoxin content should be verified on the CoA, particularly for cell-based assay applications.
  • Formulation: Refer to the product CoA or datasheet for buffer composition, protein concentration, and the presence of stabilizing excipients (e.g., glycerol, BSA). Do not assume formulation details without consulting the CoA.

Each production lot is accompanied by a CoA; always cross-reference the CoA for lot-specific data before experimental use.

Research Applications

Recombinant Human GCDH Protein is a versatile reagent applicable across multiple research domains:

  • Enzyme Kinetics and Biochemistry: Determination of kinetic parameters (Km, Vmax, kcat) for glutaryl-CoA dehydrogenation; characterization of substrate specificity and inhibitor profiling.
  • Structural Biology: Use as a reference standard or in structural studies (X-ray crystallography, cryo-EM) to elucidate GCDH oligomeric assembly and active-site architecture.
  • Disease Mechanism Research (GA1): Investigation of how pathogenic missense mutations affect GCDH folding, stability, activity, and mitochondrial import; mechanistic studies on metabolite toxicity (glutaric acid, 3-hydroxyglutaric acid).
  • Protein–Protein Interaction Studies: Mapping interaction interfaces with ETF subunits and mitochondrial chaperones involved in GCDH biogenesis.
  • Drug Discovery and Inhibitor Screening: High-throughput or targeted screening of small-molecule modulators relevant to organic acidemia therapeutic strategies.
  • Antibody Validation: Use as a positive control antigen for validating anti-GCDH antibodies in Western blot, ELISA, or immunoprecipitation assays.
  • In Vitro Reconstitution: Reconstitution of the lysine oxidation pathway segment in cell-free systems for metabolic flux analysis.

Troubleshooting Common Issues

The following troubleshooting guidance addresses frequently encountered challenges when working with Recombinant Human GCDH Protein:

ObservationProbable CauseRecommended Action
Low or absent enzymatic activityDegradation due to improper storage or excessive freeze-thaw cyclesUse freshly thawed aliquot; confirm storage at recommended temperature per CoA; check FAD cofactor supplementation in assay buffer
Precipitation or aggregationProtein concentration too high; incompatible buffer; freeze-thaw damageCentrifuge at 10,000–14,000 × g for 5 min at 4°C; dilute to working concentration; use CoA-recommended buffer
Unexpected band size on SDS-PAGEPost-translational processing; tag cleavage status; glycosylation (if applicable)Compare against expected molecular weight per datasheet; consult CoA for band pattern reference
High background in ELISA or Western blotProtein aggregation or non-specific bindingAdd 0.05–0.1% Tween-20 and blocking agent; titrate protein concentration
Inconsistent results between lotsLot-to-lot variabilityAlways request and review the CoA; run a parallel comparison experiment; contact Aladdin Scientific technical support

Frequently asked questions

What is the enzymatic function of GCDH and why is it important for research?

GCDH (Glutaryl-CoA Dehydrogenase) catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA within the mitochondrial catabolism of lysine, hydroxylysine, and tryptophan. Its importance lies in its role as the defective enzyme in Glutaric Acidemia Type 1 (GA1), making it a prime target for mechanistic, metabolic, and therapeutic research into this neurometabolic disease.

How should Recombinant Human GCDH Protein (rp374277) be stored to maintain activity?

For long-term storage, aliquot the protein into single-use volumes and store at -20°C or -80°C as specified on the lot-specific Certificate of Analysis (CoA). Avoid repeated freeze-thaw cycles, which can degrade enzymatic activity. For short-term use within one to two weeks, storage at 4°C may be appropriate; always confirm conditions on the CoA supplied with your specific lot.

What assay formats are suitable for measuring GCDH enzymatic activity?

GCDH activity is commonly measured using a coupled spectrophotometric assay in which the reduction of an artificial electron acceptor such as DCPIP (2,6-dichlorophenolindophenol) or the natural electron acceptor ETF is monitored at the appropriate absorbance wavelength in the presence of glutaryl-CoA. Fluorescence-based ETF reduction assays offer increased sensitivity. Confirm substrate and buffer compatibility with the specific lot's CoA data before establishing your assay.

Can Recombinant Human GCDH Protein be used as a positive control in immunoassays?

Yes, recombinant GCDH protein is well-suited as a positive control antigen for validating anti-GCDH antibodies in Western blot, ELISA, and immunoprecipitation experiments. Ensure the recombinant protein construct shares the epitope region recognized by your antibody of interest, particularly if a purification tag is present.

What should I do if I observe protein aggregation after thawing?

If aggregation is observed, centrifuge the thawed protein at 10,000–14,000 × g for 5 minutes at 4°C to pellet aggregates, then use the clarified supernatant. Ensure protein is thawed slowly on ice and diluted into a compatible buffer as recommended on the CoA. If aggregation persists, contact Aladdin Scientific technical support, as this may indicate a compromised lot.

References

  1. Goodman SI, Frerman FE. Organic acidemias due to defects in lysine oxidation: 2-ketoadipic acidemia and glutaric acidemia. In: Scriver CR et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2001.
  2. Kolker S, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015;38(6):1041-1057. doi:10.1007/s10545-015-9839-3
  3. Lenich AC, Goodman SI. The purification and characterization of glutaryl-coenzyme A dehydrogenase from porcine and human liver. J Biol Chem. 1986;261(9):4090-4096. PMID:3958940
  4. UniProt Consortium. UniProtKB entry Q92947 (GCDH_HUMAN). UniProt. Accessed 2024. https://www.uniprot.org/uniprot/Q92947

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.

目录: 技术文章

Da — 若无特别说明,分子量单位默认为道尔顿。   Mw — 重均分子量。   Mn — 数均分子量。

产品仅供科研与开发使用,不用于人体、动物、诊断或治疗。

引用本文

阿拉丁科学.《Recombinant Human GCDH Protein: Research Guide & Protocol》. 阿拉丁知识库,更新于 2026年11月1日。 https://www.aladdin-e.com/zh_cn/faqs/recombinant-human-gcdh-protein-research-guide-protocol-en.html
这篇文章对您有帮助吗? Yes No 有 0 人觉得有帮助